David J Ecker

This inventor holds 104 USPTO granted patents and 42 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Bioagent Detection (CPC class 536 245). Top assignees: Isis Pharmaceuticals, Inc., Ibis Biosciences, Inc., Other. Active years: 1992-2020.

USPTO Granted Patents = 104 (Patent Applications = 42)

% Patents Active = 51.9

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 4.0

ph-index = 33

Forward Citations = 3,293(Granted Patents)

Forward Citations (Not Self Cited) = 2,734(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Carlsbad, CA (US) (1992 - 2002)
Leucadia, CA (US) (1996 - 2004)
Encinitas, CA (US) (1996 - 2020)

Company Filing History:

60 out of 1,035

Isis Pharmaceuticals, Inc.

patents

43 out of 113

Ibis Biosciences, Inc.

patents

3 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2020

Loading Chart...

Areas of Expertise:

Bioagent Detection

Oligonucleotides

Pathogen Identification

Mitochondrial DNA

Nucleic Acid Sequencing

Forensic Analysis

Gene Expression

Bioagent Systems

Genome Amplification

Nucleic Acid Variants

Orthopoxviruses

Fungi Identification

104 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10662485 - Bioagent detection oligonucleotides (2020-05-26),

2. 9970061 - Bioagent detection oligonucleotides (2018-05-15),

3. 9752184 - Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy (2017-09-05),

4. 9725771 - Methods for rapid identification of pathogens in humans and animals (2017-08-08),

5. 9670538 - Nucleic acid sequencing by electrochemical detection (2017-06-06),

6. 9605260 - Alteration of neuronal gene expression by synthetic piRNAs and by alteration of piRNA function (2017-03-28),

7. 9447462 - Methods for concurrent identification and quantification of an unknown bioagent (2016-09-20),

8. 9416424 - Methods for rapid identification of pathogens in humans and animals (2016-08-16),

9. 9393564 - Bioagent detection systems, devices, and methods (2016-07-19),

10. 9149473 - Targeted whole genome amplification method for identification of pathogens (2015-10-06),

11. 8921047 - Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby (2014-12-30),

12. 8822156 - Methods for rapid identification of pathogens in humans and animals (2014-09-02),

13. 8815513 - Method for rapid detection and identification of bioagents in epidemiological and forensic investigations (2014-08-26),

14. 8802372 - Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy (2014-08-12),

15. 8691785 - Compositions and methods for non-parenteral delivery of oligonucleotides (2014-04-08),

Title: David J Ecker: Innovator in Bioagent Detection Technologies

Introduction

David J Ecker, a prolific inventor based in Encinitas, California, has made significant contributions to the field of bioagent detection. With a remarkable portfolio of 104 patents, Ecker has developed technologies that are pivotal in identifying and quantifying bacterial DNA, especially in challenging environments where contamination is a concern.

Latest Patents

Among his latest innovations are compositions, methods, and systems designed for the detection of bacterial DNA in the presence of contaminating non-bacterial DNA. His patented oligonucleotides are particularly noteworthy, as they can effectively detect small amounts of bacterial DNA amidst overwhelming quantities of contaminating human DNA. These advancements are crucial for enhancing biosecurity and improving diagnostic processes in various sectors.

Career Highlights

David Ecker has held prominent positions at leading biotechnology firms, including Isis Pharmaceuticals, Inc. and Ibis Biosciences, Inc. Throughout his career, he has been at the forefront of developing innovative solutions that address critical challenges in the detection of bioagents, showcasing his commitment to advancing scientific knowledge and technological capabilities in this area.

Collaborations

Ecker's work has been enriched through collaborative efforts with esteemed colleagues, such as Rangarajan Sampath and Steven A. Hofstadler. These partnerships have facilitated the advancement of research and the development of groundbreaking technologies in the field of bioagent detection.

Conclusion

David J Ecker's extensive contributions and innovative patents have made him a prominent figure in the biotechnology industry. His dedication to creating effective solutions for detecting bacterial DNA demonstrates the essential role that inventors play in enhancing public health and safety. As he continues to push the boundaries of innovation, Ecker remains a valuable asset to the scientific community and the future of bioagent detection technologies.